Omeros (NASDAQ:OMER) Trading 6.4% Higher – Should You Buy?

Omeros Co. (NASDAQ:OMER)’s stock price was up 6.4% during trading on Thursday . The stock traded as high as $8.96 and last traded at $9.07. Approximately 309,440 shares traded hands during trading, a decline of 42% from the average daily volume of 530,454 shares. The stock had previously closed at $8.52.

Analyst Ratings Changes

OMER has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, January 17th. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a report on Friday, March 21st. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Omeros has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Stock Performance

The firm has a market capitalization of $521.26 million, a P/E ratio of -3.87 and a beta of 2.03. The stock’s 50 day simple moving average is $8.71 and its 200 day simple moving average is $7.45.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of OMER. Charles Schwab Investment Management Inc. raised its position in Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after purchasing an additional 18,454 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares in the last quarter. HighTower Advisors LLC lifted its stake in Omeros by 7.2% in the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 4,000 shares during the period. State Street Corp grew its holdings in Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in Omeros during the 3rd quarter valued at about $305,000. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.